<scp>SGLT2</scp> Inhibitors Associated With Improved Kidney Function in Lithium‐Treated Patients With Mood Disorders: A Real‐World Historical Cohort Study

SGLT2i treatment was associated with a significant improvement in eGFR trajectory in patients with mood disorders who received long-term lithium therapy. These findings suggest a potential role for SGLT2is in mitigating lithium-associated kidney dysfunction and highlight the need for randomized controlled trials in this population.